247 related articles for article (PubMed ID: 30678445)
1. Current new challenges in the management of ulcerative colitis.
Fukuda T; Naganuma M; Kanai T
Intest Res; 2019 Jan; 17(1):36-44. PubMed ID: 30678445
[TBL] [Abstract][Full Text] [Related]
2. Promising biological therapies for ulcerative colitis: A review of the literature.
Akiho H; Yokoyama A; Abe S; Nakazono Y; Murakami M; Otsuka Y; Fukawa K; Esaki M; Niina Y; Ogino H
World J Gastrointest Pathophysiol; 2015 Nov; 6(4):219-27. PubMed ID: 26600980
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
4. Recent trends and future directions for the medical treatment of ulcerative colitis.
Naganuma M; Mizuno S; Nanki K; Sugimoto S; Kanai T
Clin J Gastroenterol; 2016 Dec; 9(6):329-336. PubMed ID: 27699641
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
7. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis.
Pugliese D; Felice C; Landi R; Papa A; Guidi L; Armuzzi A
Drug Healthc Patient Saf; 2016; 8():1-7. PubMed ID: 26893582
[TBL] [Abstract][Full Text] [Related]
8. Positioning Therapy for Ulcerative Colitis.
Grinspan A; Kornbluth A
Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
[TBL] [Abstract][Full Text] [Related]
9. Medical Therapy of Active Ulcerative Colitis.
Bürger M; Schmidt C; Teich N; Stallmach A
Viszeralmedizin; 2015 Aug; 31(4):236-45. PubMed ID: 26557831
[TBL] [Abstract][Full Text] [Related]
10. Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota.
Sun Z; Li J; Dai Y; Wang W; Shi R; Wang Z; Ding P; Lu Q; Jiang H; Pei W; Zhao X; Guo Y; Liu J; Tan X; Mao T
Front Microbiol; 2020; 11():731. PubMed ID: 32425906
[TBL] [Abstract][Full Text] [Related]
11. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
12. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
Allocca M; Fiorino G; Gilardi D; Preatoni P; Papa A; Peyrin-Biroulet L; Danese S
Curr Drug Targets; 2018; 19(7):748-756. PubMed ID: 27231106
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
14. Contemporary Management of Ulcerative Colitis.
Vanga R; Long MD
Curr Gastroenterol Rep; 2018 Mar; 20(3):12. PubMed ID: 29589185
[TBL] [Abstract][Full Text] [Related]
15. Update on the Use of Biologic Therapy in Ulcerative Colitis.
Aggarwal A; Sabol T; Vaziri H
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):155-167. PubMed ID: 28120279
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
17. Golimumab for the treatment of ulcerative colitis.
Löwenberg M; de Boer NKh; Hoentjen F
Clin Exp Gastroenterol; 2014; 7():53-9. PubMed ID: 24648749
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
